AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10695097
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg nimesulide
Trial: 22480204
Drug: UP446 250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP446 250 mg/day
Trial: 22480204
Drug: UP446 500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UP446 500 mg/day
Trial: 22480204
Drug: Placebo (CMC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (CMC capsule)
Trial: 21084042
Drug: FPNS 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPNS 200 µg
Trial: 21084042
Drug: FPNS (100,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FPNS (100, 200, 400, and 800 µg)
Trial: 22064877
Drug: Iron-fortified formula
RxNorm normalized name: INFANT FORMULA SMA IRON FORTIFIED CONC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron-fortified formula (mean, 12.7 mg/L)
Trial: 22064877
Drug: Low-iron formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-iron formula (mean, 2.3 mg/L)
Trial: 19818062
Drug: Trospium chloride
RxNorm normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Trospium chloride ER 60 mg
Trial: 14754497
Drug: Albendazole for
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole for 7 days (400 mg/day)
Trial: 14754497
Drug: Albendazole for
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole for 5 days (400 mg/day)
Trial: 14754497
Drug: Albendazole for
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole for 3 days (400 mg/day)
Trial: 11509075
Drug: Physical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical therapy for the affected side (1 hour, 3 times a week for 6 weeks) combined with mental practice (listening to an audiotape 2 times a week, plus additional home practice)
Trial: 8425995
Drug: Intermittent transdermal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent transdermal nitroglycerin
Trial: 8945675
Drug: Continuous transdermal
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous transdermal nitroglycerin
Trial: 3434740
Drug: Intravenous atropine
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous atropine 600 micrograms
Trial: 28131632
Drug: CD56-enriched donor
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD56-enriched donor cell infusion after post-transplantation cyclophosphamide (PTCy)
Trial: 28131632
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (20 patients without CD56-enriched donor cell infusion)
Trial: 28131632
Drug: CD56-enriched donor
RxNorm normalized name: Donor Human Stool
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CD56-enriched donor cell infusion after PTCy
Trial: 25373391
Drug: Minocycline 100
RxNorm normalized name: minocycline 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minocycline 100 mg once a day
Trial: 25373391
Drug: Amitriptyline 25
RxNorm normalized name: amitriptyline 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 25 mg once a day
Trial: 23406489
Drug: 1 Day
RxNorm normalized name: ZonaCort 11 Day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 Day Acuvue Moist for Astigmatism (daily disposable toric soft lens)
Trial: 23406489
Drug: Acuvue Oasys
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acuvue Oasys for Astigmatism (2-weekly replacement, re-usable toric soft lens)
Trial: 11124758
Drug: 15 g
RxNorm normalized name: 15 g/31 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 g D‐tagatose added to the diet daily
Trial: 7942652
Drug: Carbamide peroxide
RxNorm normalized name: Carbamide Peroxide
DrugBank: Carbamide peroxide (DB11129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbamide peroxide home bleaching agent for 72 hours before bonding
Trial: 31223042
Drug: 19.5 mg
RxNorm normalized name: camphor 19.5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 19.5 mg LNG-IUS
Trial: 18490865
Drug: Methyl-cellulose placebo
RxNorm normalized name: Methyl cellulose
DrugBank: Methylcellulose (DB11228)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methyl-cellulose placebo gel
Trial: 30670043
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group with no alert for tobacco treatment.
Trial: 18720937
Drug: Somatostatin 6
RxNorm normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin 6 mg/day infused separately
Trial: 18720937
Drug: Somatostatin 6
RxNorm normalized name: Somatostatine
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin 6 mg/day added to TPN
Trial: 18720937
Drug: Pre-treatment serum
RxNorm normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-treatment serum level
Trial: 18720937
Drug: Post-treatment serum
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment serum level
Trial: 12447222
Drug: No. 23
RxNorm normalized name: vehicle base no. 23
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No. 23 dental explorer and air-water spray
Trial: 10955129
Drug: Propafenone 600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 600 mg as a first oral dose followed after 8 hrs by 150 mg (Group A)
Trial: 10955129
Drug: Propafenone 300
RxNorm normalized name: propafenone 300 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 300 mg as a first dose, followed by the same dose 3 and again 8 hrs later (Group B)
Trial: 10955129
Drug: Propafenone 150
RxNorm normalized name: propafenone 150 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propafenone 150 mg every 3 hrs, up to a total dose of 600 mg (Group C)
Trial: 8551493
Drug: Celiprolol therapy
RxNorm normalized name: celiprolol
DrugBank: Celiprolol (DB04846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celiprolol therapy
Trial: 29017497
Drug: Vildagliptin (DPP-4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (DPP-4 inhibitor) add-on group
Trial: 29017497
Drug: High-dose metformin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose metformin (double dose)
Trial: 21910074
Drug: Chinese herbal
RxNorm normalized name: GINGER 28 mg in 100 mL TOPICAL OIL [Pain Relief Honzo Seika Chinese Herbal Aroma Oil]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chinese herbal medicine for strengthening qi, nourishing yin, and removing stasis combined with hydroxychloroquine sulfate tablet (HCQ) for 3 months
Trial: 21910074
Drug: Hydroxychloroquine sulfate
RxNorm normalized name: Hydroxychloroquine Sulfate
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine sulfate tablet (HCQ) only for 3 months
Trial: 11079363
Drug: Trazodone 200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trazodone 200 mg/day
Trial: 6328288
Drug: Oral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral feeding with adequate vitamin D and phosphate supplementation
Trial: 6328288
Drug: Parenteral feeding
RxNorm normalized name: SET,FEEDING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parenteral feeding with vitamin D supplementation
Trial: 25862567
Drug: Sequential regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential regimen of infusional 5-fluorouracil and leucovorin plus irinotecan followed by cisplatin and docetaxel
Trial: 24691218
Drug: Web-based physiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Web-based physiotherapy (12 weeks, twice per week)
Trial: 22015737
Drug: Benzocaine 8
RxNorm normalized name: benzocaine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine 8 mg lozenge
Trial: 20039221
Drug: Midazolam 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 0.05 mg . kg(‐1)
Trial: 12100764
Drug: Salbutamol metered-dose
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol metered-dose inhaler (MDI) 1.2 mg
Trial: 12100764
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of salbutamol 1.2 mg
Trial: 8767529
Drug: Melphalan/prednisone (MP)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Melphalan/prednisone (MP) as first-line treatment in 84 patients (74%)
Trial: 1858732
Drug: Rice flour
RxNorm normalized name: Rice Flour
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rice flour solution
Trial: 1858732
Drug: World Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: World Health Organization rehydration solution by gastric infusion
Trial: 1858732
Drug: World Health
RxNorm normalized name: Healthy Mama
FDA approved: no
EMA approved: no
PMDA approved: no
Description: World Health Organization rehydration solution orally
Trial: 31514186
Drug: Increased antiphosphatidylserine
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased antiphosphatidylserine antibodies (aPS) in patients with abnormal renal function
Trial: 31514186
Drug: Increased antiphosphatidylserine
RxNorm normalized name: Phosphatidylserine
DrugBank: Phosphatidyl serine (DB00144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Increased antiphosphatidylserine antibodies (aPS) in patients with normal renal function
Trial: 26806045
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (3 g/d)
Trial: 24886151
Drug: Supported cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supported cognitive behavioral therapy self-help (CBTsh) supported by mental health paraprofessionals
Trial: 22424003
Drug: Routine supplemental
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine supplemental oxygen therapy
Trial: 17931241
Drug: Gentamicin-collagen implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gentamicin-collagen implant (10 cm x 10 cm)
Trial: 17931241
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no gentamicin-collagen implant)
Trial: 16219105
Drug: Chemoradiation using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine infusions weekly over 4 weeks.
Trial: 16219105
Drug: Chemoradiation using
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoradiation using IMRT combined with gemcitabine and simultaneous cetuximab infusions, followed by gemcitabine weekly over 4 weeks and cetuximab infusions over 12 weeks.
Trial: 7318340
Drug: Saline infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline infusion (2.25 mmol of Na+/kg) over 30 min
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 12 weeks
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 12 weeks
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg plus ribavirin for 8 weeks
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg for 8 weeks
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 100 mg plus ribavirin for 8 weeks
Trial: 26551051
Drug: Sofosbuvir, 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir, 400 mg, with velpatasvir, 25 mg for 8 weeks
Trial: 21537591
Drug: Oxa-Gel
RxNorm normalized name: (Z)-(2R,5R)-3-(2-Hydroxyethylidene)-7-oxo-4-oxa-1-azabicyclo(3.2.0)heptane-2-carboxylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxa-Gel
Trial: 19281503
Drug: Immediate transmucosal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate transmucosal tapered-effect (TE) implants placed in molar extraction sockets with buccal bone dehiscence
Trial: 19281503
Drug: Implants placed
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Implants placed in healed molar sites (control sites)
Trial: 11678784
Drug: Oxy-XL 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oxy-XL 10 mg
Trial: 11678784
Drug: IR-Oxy 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IR-Oxy 5 mg
Trial: 9832663
Drug: Warmed saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warmed saline solution
Trial: 8076768
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (8.4-336 MU)
Trial: 8076768
Drug: Interferon treatment
RxNorm normalized name: Interferon Gamma
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Interferon treatment (336 MU)
Trial: 8076768
Drug: Other treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other treatment protocols (lower dosages)
Trial: 2642538
Drug: Chemoendocrine therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemoendocrine therapy for 1 year
Trial: 2642538
Drug: Endocrine therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine therapy alone for 1 year
Trial: 322648
Drug: Timolol 1.5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Timolol 1.5% solution
Trial: 22908891
Drug: Single-dose ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-dose ceftriaxone during induction of anesthesia
Trial: 22908891
Drug: Short-course oral
RxNorm normalized name: short ragweed pollen extract Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course oral third-generation cephalosporin after ceftriaxone until nephrostomy catheter withdrawal
Trial: 21660077
Drug: Pioglitazone 45
RxNorm normalized name: pioglitazone 45 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pioglitazone 45 mg/day for 12 months (n = 10)
Trial: 21660077
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy with pioglitazone (45 mg/day) and exenatide (10 µg subcutaneously twice daily) for 12 months (n = 11)
Trial: 11566520
Drug: Subconjunctival injection
RxNorm normalized name: STREPTOMYCES GRISEUS 0.05 g in 1 mL SUBCONJUNCTIVAL INJECTION, SOLUTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subconjunctival injection of dexamethasone
Trial: 11566520
Drug: No subconjunctival
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No subconjunctival steroid injection
Trial: 9626918
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of formoterol
Trial: 3585263
Drug: Triple antibiotic
RxNorm normalized name: Triple Antibiotic
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triple antibiotic ointment (neomycin, polymyxin B, bacitracin) applied twice a day
Trial: 3585263
Drug: Other antibiotic
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotic ointment
Trial: 21034744
Drug: Telaprevir 750
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir 750 mg every 8 hours with peginterferon alfa-2a and ribavirin
Trial: 21034744
Drug: Telaprevir 1125
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Telaprevir 1125 mg every 12 hours with peginterferon alfa-2a and ribavirin
Trial: 12568736
Drug: Continuous combined
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous combined hormone replacement therapy (Premelle)
Trial: 8725417
Drug: Midazolam at
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam at a target plasma concentration of 150 ng/mL
Trial: 8725417
Drug: Midazolam at
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Midazolam at a target plasma concentration of 300 ng/mL
Trial: 1561909
Drug: Buspirone 30
RxNorm normalized name: busPIRone 30 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buspirone 30 mg/d
Trial: 3898348
Drug: Anticholinergic (glycopyrrolate,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic (glycopyrrolate, 2 mg three times daily) and antacid (60 ml/day)
Trial: 3898348
Drug: Anticholinergic/antacid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticholinergic/antacid
Trial: 30539891
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (IFA tablets without direct supervision)
Trial: 22538329
Drug: Intensive low-density
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive low-density lipoprotein cholesterol and blood pressure lowering therapy
Trial: 17158415
Drug: 400,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400,000 IU vitamin A in 2 divided doses
Trial: 17158415
Drug: 200,000 IU
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200,000 IU vitamin A as a single dose plus placebo
Trial: 17158415
Drug: Post-treatment serum
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Post-treatment serum retinol concentrations
Trial: 10884642
Drug: Controlled injection
RxNorm normalized name: Afeditab CR
DrugBank: Nifedipine (DB01115)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Controlled injection pressure system
Trial: 10884642
Drug: Conventional atraumatic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional atraumatic syringe injection technique
Trial: 1593854
Drug: Low protein
RxNorm normalized name: Low protein mix
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low protein diet (0.55 g/kg/day)
Trial: 1593854
Drug: High protein
RxNorm normalized name: Vital High Protein
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High protein diet (2 g/kg/day)
Trial: 6140202
Drug: High-dose 6-methylprednisolone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose 6-methylprednisolone
Trial: 6140202
Drug: 6-methylprednisolone combined
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 6-methylprednisolone combined with 3 g of sulfasalazine
Trial: 6140202
Drug: 3 g
RxNorm normalized name: Molds 3 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g of sulfasalazine alone
Trial: 6140202
Drug: Continuous administration
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous administration of low doses of 6-methylprednisolone or the combination regimen
Trial: 30880285
Drug: CRP-guided antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-guided antibiotic treatment (CRP ≥50 mg·L‐1)
Trial: 30880285
Drug: CRP-guided antibiotic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CRP-guided antibiotic treatment
Trial: 29059190
Drug: Annual mass
RxNorm normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Annual mass drug administration (MDA) of praziquantel
Trial: 17299107
Drug: Beverage containing
RxNorm normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beverage containing green tea catechins, caffeine, and calcium (3 x 250-mL servings for 3 days)
Trial: 11243304
Drug: Plasma leptin
RxNorm normalized name: leptin
DrugBank: Leptin (DB05098)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma leptin levels (mean, 11.1 ng/mL for boys and 19.7 ng/mL for girls in the highest quintile)
Trial: 8153985
Drug: Albendazole 600
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 600 mg single dose
Trial: 8153985
Drug: Albendazole 800
RxNorm normalized name: Albendazole
DrugBank: Albendazole (DB00518)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Albendazole 800 mg single dose
Trial: 8153985
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg daily for 3 days
Trial: 8613282
Drug: Albendazole 400
RxNorm normalized name: albendazole 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Albendazole 400 mg daily for 5 days
Trial: 2896600
Drug: Almitrine bismesylate
RxNorm normalized name: almitrine dimesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almitrine bismesylate (1.5 mg/kg/day for one year)
Trial: 31030594
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (terbinafine 250 mg + itraconazole 200 mg)